All In Biotech

Drug Trial Radar · NCT04492293

An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

A Phase 2, Multicenter, Single Arm, Open-lable Study of ICP-192 in Subjects With Surgically Unresectable or Metastatic Bladder Urothelial Cancer With FGFR Genetic Aberrations.

Last checked: Nov 19, 2026Latest source record: Feb 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

115

Planned (sponsor's estimate)

Start

May 27, 2020

Primary completion

Dec 31, 2024

Study completion Jun 30, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, multicenter, single arm, open-lable study of ICP-192. The purpose of this study is to evaluate efficacy of ICP-192 in subjects with surgically unresectable or metastatic bladder urothelial cancer.

Conditions

  • Bladder Urothelial Cancer

Interventions

  • ICP-192Drug

    ICP-192 is a white, round, uncoated table

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: From the time of first dose until objective disease progression, an average of 6 months

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The fifth Medical Center of People's Liberation Army General Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • The First Affiliated Hospital of Suzhou University

    Suzhou, Jiangsu, China · Recruiting

  • The First Hospital of JiLin University

    Jilin City, Jilin, China · Recruiting

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China · Recruiting

  • Shandong University Qilu Hospital

    Jinan, Shandong, China · Recruiting

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China · Recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The Second Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.